Literature DB >> 27612968

Dose, Plasma Level, and Treatment Outcome Among Methadone Patients in Shanghai, China.

Haifeng Jiang1, Maureen Hillhouse2, Jiang Du1, Shujun Pan1, Ang Alfonso2, Jun Wang3, Zhirong Zhou4, Weijun Yuan5, Walter Ling2, Min Zhao6.   

Abstract

The purpose of this study was to investigate the blood levels of methadone in participants receiving methadone for the treatment of opioid dependence. After stabilization on methadone for four weeks, blood samples from 95 participants were collected between treatment weeks 4 and 12, before and after receiving doses of methadone, and its blood levels were measured. A multiple linear regression model was used to examine the association between methadone blood levels and the outcomes of methadone maintenance treatment (MMT). Outcome differences between participants who had high (≥2) or low (<2) peak-to-trough ratios were also compared using an independent sample t-test. The blood level of methadone was not correlated with the clinical outcome of MMT with the moderate range of doses given. However, the retention of patients who had a free peak-to-trough ratio >2 was significantly poorer than those whose ratio was <2. Thus, monitoring plasma methadone levels is unlikely to be effective for guiding dosing decisions in situations where compliance with MMT is already very high or when the methadone dose is no longer the dominant factor in determining the clinical outcome. However, monitoring plasma methadone levels is still helpful for guiding the dosage for patients with a rapid metabolism.

Entities:  

Keywords:  Metabolism; Methadone; Plasma level; Treatment outcome

Mesh:

Substances:

Year:  2016        PMID: 27612968      PMCID: PMC5563833          DOI: 10.1007/s12264-016-0059-0

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  12 in total

1.  The use of plasma levels to optimize methadone maintenance treatment.

Authors:  N Loimer; R Schmid
Journal:  Drug Alcohol Depend       Date:  1992-08       Impact factor: 4.492

2.  Who uses methadone services in China? Monitoring the world's largest methadone programme.

Authors:  Sheena G Sullivan; Zunyou Wu; Keming Rou; Lin Pang; Wei Luo; Changhe Wang; Xiaobin Cao; Wenyuan Yin; Enwu Liu; Guodong Mi
Journal:  Addiction       Date:  2015-01       Impact factor: 6.526

3.  Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships.

Authors:  K R Dyer; D J Foster; J M White; A A Somogyi; A Menelaou; F Bochner
Journal:  Clin Pharmacol Ther       Date:  1999-06       Impact factor: 6.875

4.  Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.

Authors:  Séverine Crettol; Jean-Jacques Déglon; Jacques Besson; Marina Croquette-Krokkar; Isabelle Gothuey; Robert Hämmig; Martine Monnat; Hardy Hüttemann; Pierre Baumann; Chin B Eap
Journal:  Clin Pharmacol Ther       Date:  2005-12       Impact factor: 6.875

5.  Methadone trough levels in pregnancy.

Authors:  John Drozdick; Vincenzo Berghella; MaryKay Hill; Karol Kaltenbach
Journal:  Am J Obstet Gynecol       Date:  2002-11       Impact factor: 8.661

6.  A qualitative study exploring the reason for low dosage of methadone prescribed in the MMT clinics in China.

Authors:  Chunqing Lin; Roger Detels
Journal:  Drug Alcohol Depend       Date:  2011-02-09       Impact factor: 4.492

7.  Alpha 1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome.

Authors:  M J Garrido; C Aguirre; I F Trocóniz; M Marot; M Valle; M K Zamacona; R Calvo
Journal:  Int J Clin Pharmacol Ther       Date:  2000-01       Impact factor: 1.366

Review 8.  Interindividual variability of methadone response: impact of genetic polymorphism.

Authors:  Yongfang Li; Jean-Pierre Kantelip; Pauline Gerritsen-van Schieveen; Siamak Davani
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

9.  Time to first treatment interruption in the Chinese methadone maintenance treatment programme.

Authors:  Sheena G Sullivan; Zunyou Wu; Roger Detels
Journal:  Drug Alcohol Depend       Date:  2013-07-26       Impact factor: 4.492

10.  Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures.

Authors:  M I Nilsson; L Grönbladh; E Widerlöv; E Anggård
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more
  4 in total

1.  Special Topic on Mental Health and Addiction.

Authors:  Lin Lu; Wenhua Zhou
Journal:  Neurosci Bull       Date:  2016-11-21       Impact factor: 5.203

Review 2.  National Institute on Drug Abuse International Program: improving opioid use disorder treatment through international research training.

Authors:  Steven W Gust; Judy McCormally
Journal:  Curr Opin Psychiatry       Date:  2018-07       Impact factor: 4.741

Review 3.  Drug addiction: a curable mental disorder?

Authors:  Jian-Feng Liu; Jun-Xu Li
Journal:  Acta Pharmacol Sin       Date:  2018-10-31       Impact factor: 6.150

4.  A longitudinal and case-control study of dropout among drug users in methadone maintenance treatment in Haiphong, Vietnam.

Authors:  Pham Minh Khue; Nguyen Thi Tham; Dinh Thi Thanh Mai; Pham Van Thuc; Vu Minh Thuc; Pham Van Han; Christina Lindan
Journal:  Harm Reduct J       Date:  2017-08-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.